Our data indicate that prediction of VTE in lymphoma and MM patients may be more accurate if a limited set of genetic predictors (FV rs6025, serpinA10 rs2232698 and FXIII-A Val34Leu), clinical predictors (ECOG, immobilization, the aggressiveness of the neoplasia and treatment with dexamethasone), and haemostatic biomarkers (D-dimer, FVIII and total PS activity) are included in a new risk score, which could contribute to personalized, risk-stratified patient management in the future. The gene discussed is F5; the disease is Miyoshi myopathy.